Pipeline

Precision oncology

NuclearMediX is building a platform-driven radiopharmaceutical pipeline, combining clinically validated assets with a scalable engine for expansion.

Development pipeline

Oncology

DiagnosticTherapeutic
Oncology programmes by target, indication and development stage
CandidateTargetIndication Development stage
DiscoveryPreclinicalPhase 1Phase 2Phase 3
NMX-001AFETODiagnostic TargetSSTR2 IndicationNeuroendocrine tumours Phase 2 completed
NMX-001AFETODiagnostic TargetSSTR2 IndicationSmall cell lung cancer IND-enabling
NMX-001BFETO-AlphaTherapeutic TargetSSTR2 IndicationNETs, SCLC, NPC Lead optimisation
NMX-002ADiagnostic TargetTarget A IndicationSolid tumours Lead optimisation
NMX-002BTherapeutic TargetTarget A IndicationSolid tumours Research
NMX-003ADiagnostic TargetTarget B IndicationSolid tumours Research
NMX-003BTherapeutic TargetTarget B IndicationSolid tumours Research

NETs: neuroendocrine tumours · SCLC: small cell lung cancer · NPC: nasopharyngeal carcinoma
IND: investigational new drug · SSTR2: somatostatin receptor 2

NMX-001A (FETO)

NMX-001A is an 18F-labelled somatostatin receptor-targeted PET radiotracer designed to image SSTR-expressing tumours, with a focus on neuroendocrine tumours (NETs).

Why it matters

  • Clinically validated target biology (SSTR2)
  • 18F enables broader distribution reach vs 68Ga
  • Cassette-compatible manufacturing for multi-site replication

Discovery Engine

Our discovery engine uses the same modular rules to generate additional programmes over time:

Validated Biology
Click chemistry-enabled design
Radionuclide flexibility
Manufacturing-ready chemistry
Programme Detail

About FETO

FETO

Chemical name: [18F]FET-βAG-TOCA.

SSTR-targeted PET

Designed to support reliable supply of SSTR-targeted PET radiotracers.

NETs

The initial application remains neuroendocrine tumours, with potential broader SSTR-positive oncology use.